Group O leukocyte‑free whole blood: storage effects and inflammation
Official title: grouP O wholE blooD (LTO-WB): storagE leSion impacT And infLammation
Run by Etablissement Français du Sang · NCT06809010 · Data updated 2026-11-12
This project tests whether group O leukocyte‑free whole blood (LTOWB) causes different inflammatory and biological changes than standard separated blood products using donations from healthy adult blood donors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Etablissement Français du Sang Academic / other |
| Locations | 1 site (Saint-Etienne) |
| Status | Recruiting |
| Started | March 12, 2025 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | August 6, 2025 |
| Trial ID | NCT06809010 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults who are eligible for blood donation—aged 18–70 for whole blood donation (18–65 for apheresis), weigh at least 50 kg, and meet standard donor health criteria—are ideal candidates.
✕Probably not a fit
People who need immediate transfusion, are ineligible to donate, or expect direct medical treatment from participation should not expect personal clinical benefit from joining this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study compares inflammatory and laboratory characteristics of LTOWB produced by the military transfusion center with conventional blood products prepared by the national blood service. Researchers will use in vitro and in vivo tools and biomarker panels to compare platelet‑related, red blood cell‑related, and circulating inflammatory molecule differences between LTOWB and pooled or apheresis platelets, RBC concentrates, and fresh frozen plasma. Samples come from consenting healthy donors who meet standard donation criteria and are processed according to each center's procedures. Results aim to define biomarkers that could guide optimal use of LTOWB in operational and civilian settings.
Why it matters
Potential benefit: If successful, the work could clarify inflammatory risks of LTOWB and help guide safer use of whole blood in trauma and austere environments.
How similar studies have gone: Previous clinical work supports LTOWB's effectiveness for hemorrhage control, but the product's platelet‑linked inflammatory effects have not been fully studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Self-referred donors eligible for blood donation (whole blood and/or platelet/plasma apheresis), meeting the following inclusion criteria: * Be in good health * Weigh at least 50 kg * Must be between 18 and 70 years of age for whole blood donation and between 18 and 65 years of age for plasma/platelet donation by apheresis. Exclusion Criteria: Subjects ineligible to donate blood
Where it's running
-
Maison du don de l'EFS Auvergne Rhônes-Alpes
Saint-Etienne, France Recruiting
Study contacts
- Study coordinator: Hind HAMZEH-COGNASSE, PhD, HDR
- Email: hind.hamzeh@univ-st-etienne.fr
- Phone: +33 477 421 400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Plasma transfusion to protect newborns exposed to chikungunya from brain inflammation
This trial will test whether giving plasma from a recent chikungunya-infected donor to newborns whose mothers had chikungunya around delivery helps prevent encephalitis or encephalopathy in the first five days of life.
-
Comparing blood transfusion thresholds in patients on ECMO
This study tests whether giving fewer blood transfusions is safe and effective for adults on ECMO compared to giving more transfusions.
-
Effect of blood volume management during bone tumor surgery
This study is testing if a method called acute normovolemic hemodilution can help reduce the need for blood transfusions during bone tumor surgeries for patients aged 18 to 75.
-
Combined iron supplementation to reduce blood transfusions in cardiac surgery
This study tests if a new combination of iron, a hormone, and vitamin C can help adults with iron-deficiency anemia needing heart surgery avoid blood transfusions.
-
Investigating the role of platelets in brain tumors
This study looks at how platelets might affect the growth and spread of brain tumors, especially gliomas, by collecting blood and tumor samples to better understand their interactions.
-
Collection and distribution of blood components from healthy donors for research use
This study is about collecting blood from healthy volunteers to help researchers at NIH and FDA with their lab work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.